

DR LITAO ZHANG (Orcid ID : 0000-0003-4918-611X)

Article type : Brief Report

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Litao Zhang^{1,2}, Xinsheng Yan³, Qingkun Fan¹, Haiyan Liu³, Xintian Liu⁴, Zejin Liu³, Zhenlu Zhang^{1, 2,3}

¹ Laboratory Medicine, Wuhan Asia Heart Hospital, No.753 Jingnan Avenue, Wuhan, China, 430022

² Physiology Group, School of Nursing, Wuhan Institute of Design and Science, No.1 Yangqiaohu Avenue, Wuhan, China, 430205.

³ Laboratory Medicine, Wuhan Asia General Hospital, No.300 Taizihu north road, Wuhan, China. 430056

⁴ Department of Cardiology, Wuhan Asia Heart Hospital, No.753 Jingnan Avenue, Wuhan, China, 430022

Litao Zhang, Xinsheng Yan contribute equally to this work.

Address correspondence to:

Zhenlu Zhang

Laboratory Medicine, Wuhan Asia Heart Hospital. No.753 Jingnan Avenue, Wuhan, China, 430022. Phone: 86-18963980041; Fax: 86-2785854036

E-mail address: zhenluzhangwh@163.com

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/JTH.14859](#)

This article is protected by copyright. All rights reserved

Bullet points

Measuring D-dimer had been recommended for Covid-19 patients, however, the optimal cutoff for D-dimer remains to be well-established.

D-dimer = 2.0 ug/ml (fourfold increase) on admission might be the optimum cutoff to predict in-hospital mortality for Covid-19.

The in-hospital mortality was significant higher in patients with D-dimer \geq 2.0 ug/ml than those who had D-dimer < 2.0 ug/ml on admission.

Among routine tests, D-dimer might be the best early marker to improve management of Covid-19 patients.

Abstract

Background: The outbreak of the coronavirus disease 2019 (Covid-19) shows a global spreading trend. Early and effective predictors of clinical outcomes is urgent needed to improve management of Covid-19 patients.

Objective: The aim of the present study was to evaluate whether elevated D-dimer levels could predict mortality in patients with Covid-19.

Methods: Patients with laboratory confirmed Covid-19 were retrospective enrolled in Wuhan Asia General Hospital from January 12, 2020 to March 15, 2020. D-dimer levels on admission, and death events were collected to calculate the optimum cutoff using receiver operating characteristic curve. According to the cutoff, the subjects were divided into two groups. Then the in-hospital mortality between two groups were compared to assess the predictive value of D-dimer level.

Results: A total of 343 eligible patients were enrolled in the study. The optimum cutoff value of D-dimer to predict in-hospital mortality was 2.0 $\mu\text{g/ml}$ with a sensitivity of 92.3% and a specificity of 83.3%. There were 67 patients with D-dimer $\geq 2.0 \mu\text{g/ml}$, and 267 patients with D-dimer $< 2.0 \mu\text{g/ml}$ on admission. 13 deaths occurred during hospitalization. Patients with D-dimer levels $\geq 2.0 \mu\text{g/ml}$ had a higher incidence of mortality when comparing to those who with D-dimer levels $< 2.0 \mu\text{g/ml}$ (12/67 vs 1/267, $P < 0.001$, HR:51.5, 95%CI:12.9-206.7).

Conclusions:

D-dimer on admission greater than 2.0 $\mu\text{g/mL}$ (fourfold increase) could effectively predict in-hospital mortality in patients with Covid-19, which indicated D-dimer could be an early and helpful marker to improve management of Covid-19 patients. (Chinese Clinical Trial Registry: ChiCTR2000031428)

Keywords: coronavirus disease; SARS-CoV-2; D-dimer; mortality; prognosis

Introduction

The novel coronavirus, designated SARS-CoV-2, has caused a global outbreak of respiratory illness termed coronavirus disease 2019 (Covid-19) since December, 2019 and are still spreading quickly in more than 100 countries.[1-3] There have been more than 600 thousand patients with confirmed Covid-19 worldwide by the end of March, 2020.[3-5] One of the key issues has been the very high volume of patients presenting to health centers or hospitals during the outbreak. It clearly overwhelms the human and mechanistic capacities available, especially the need for critical care support. As such, risk stratification measures would clearly be helpful[5, 6]. Therefore, early and effective predictors of clinical outcomes are urgent needed for risk stratification of Covid-19 patients. D-dimer originates from the formation and lysis of cross-linked fibrin and reflects activation of coagulation and fibrinolysis[7]. It has been reported that Covid-19 was associated with hemostatic abnormalities, and markedly elevated D-dimer levels were observed in those non-survivors[8]. However, the prognosis value and the optimal cut-off value for D-dimer on admission to predict mortality have not been well evaluated.

Methods

Study design and participants

The study was a retrospective study conducted in Wuhan Asia General Hospital (Wuhan, China), which was a designated hospital for Covid-19 patients. Adult (aged 18 years or elder) patients with laboratory-confirmed Covid-19 between January 12, 2020 and March 15, 2020 were retrospectively screened. The diagnosis of Covid-19 was according to World Health Organization interim guidance[9] and confirmed by RNA detection of the SARS-CoV-2 in onsite clinical laboratory. A total of 343 participants who had a D-dimer level on admission and had a definite outcome (dead or survival) were enrolled. The study was approved and the requirement for informed consent was waived by the Ethics Commission (WAGHMEC-KY-202004).

Data collection

All clinical, laboratory, and outcome data were extracted from electronic medical records using a standardized data collection form. All data were checked by two physicians (SY and XL) and a third researcher (ZL) adjudicated any difference in interpretation between the two primary

reviewers.

Laboratory assay and Intervention

Blood samples were collected within 24 hours after admission to perform routine laboratory tests, such as blood count, coagulation profile, serum biochemical tests (including renal and liver function) et al in onsite laboratory. D-dimer was determined on CS5100 automatic coagulation analyzer (Sysmex, Kobe, Japan) by utilizing a latex-enhanced photometric immunoassay (Siemens, Marburg, Germany). Inter and intra-day variability coefficients were 3.41% and 4.22%. The laboratory reference range was 0-0.5 µg/ml. The D-dimer result was expressed in µg/ml FEU (Fibrinogen Equivalent Unit). All measurements were done within 2 hours after blood sampling.

Statistical analysis

Continuous and categorical variables were presented as mean \pm standard deviation or median (Inter-quartile range, IQR), as appropriate. Categorical variables were presented as n (%). Event frequencies were compared with chi-square test. Other comparisons between two groups were made with unpaired Student t test or Mann-Whitney U test. The optimal D-dimer cutoff point and C-statistic of routine tests were evaluated by receiver operator characteristic (ROC) curve. The outcomes were compared by Kaplan-Meier survival analysis. Hazard ratio (HR) and 95% confidential interval (95% CI) were calculated by log-rank tests. The prognostic values of D-dimer and clinical variables were analyzed with Cox-proportional hazard models. A value of $p < 0.05$ was accepted as statistically significant. The statistical software package MedCalc Statistical Software (version 16.2, Ostend, Belgium) were used for analyses.

Results

Baseline characteristics and Establishing optimum cutoff value for D-Dimer

Of 343 eligible patients, the median age was 62 years (IQR, 48-69 years), ranging from 18 years to 92 years. 37.6% (129/343) patients were older than 65 years. 50.3% (174/343) patients were female. Listed in Table 1 are the basic clinical characteristics of the patients, including age, gender, comorbidities, and routine laboratory results on admission. A total of 13 all-cause deaths occurred during hospitalization. The optimum cutoff value for D-dimer to predict all-cause deaths was 2.0 µg/ml using ROC curve (Figure 1) with a sensitivity of 92.3% and a specificity of 83.3%.

Area under ROC curve for all-cause deaths was 0.89. Among routine laboratory tests, D-dimer has the highest C-index to predict in-hospital mortality in Covid-19 patients (Table 2). Besides, The C-indices indicates lymphocyte, prothrombin time, and C-reaction protein are also strong predictors for these patients (Table 2).

According to the optimum cutoff value, 276 patients' D-dimer levels on admission were less than 2.0 $\mu\text{g/ml}$, and 67 patients had D-dimer levels over 2.0 $\mu\text{g/ml}$. Compared to those patients with D-dimer levels below 2.0 $\mu\text{g/ml}$, patients with D-dimer levels $\geq 2.0 \mu\text{g/ml}$ had a higher incidence of underlying disease, such as diabetes ($p=0.007$), hypertension ($p<0.001$), coronary heart disease ($p=0.02$) and stroke history ($p<0.001$). Additionally, lower level of lymphocyte ($p<0.001$), hemoglobin ($p=0.003$), platelet count ($p=0.009$) and higher level of neutrophil ($p<0.001$), c-reaction protein ($p<0.001$), and prothrombin time ($p<0.001$) were also observed in those with D-dimer levels $\geq 2.0 \mu\text{g/ml}$.

High D-dimer levels to predict mortality

A total of 13 death events occurred during hospitalization, 12 of them were observed among patients with D-dimer levels $\geq 2.0 \mu\text{g/ml}$ on admission as compared with only one such event in those with negative D-dimer levels ($<2.0 \mu\text{g/ml}$) on admission (12/67 vs. 1/276). Kaplan-Meier Survival Curves (Figure 2) for D-dimer levels showed that D-dimer level $\geq 2.0 \mu\text{g/ml}$ was the significant predictor of subsequent deaths ($P<0.001$, HR:51.5, 95%CI:12.9-206.7). Statistical significance of separation between two groups was achieved at seven days. Cox proportional hazard analysis showed that high D-dimer level was also a significant determinant ($p=0.003$, adjusted HR:22.4; 95% CI: 2.86-175.7) after adjustment of gender, age, with or without underlying disease.

Discussion

The main finding of this study is that D-dimer on admission greater than 2.0 $\mu\text{g/mL}$ was the independent predictor of in hospital death for patients with Covid-19. This finding provides a well-established cutoff value to identify those patients with Covid-19 who have poor prognosis at an early stage.

D-dimer elevation has been reported to be one of the commonest laboratory findings noted in

Covid-19 patients requiring hospitalization. Guan and colleagues analyzed 1099 patients with laboratory-confirmed Covid-19 from over 550 hospitals in China[5], and found the non-survivors had a significantly higher D-dimer (median: 2.12 $\mu\text{g/ml}$) than that of survivors (median: 0.61 $\mu\text{g/ml}$). Similarly, Ning T et al also observed abnormal coagulation results, especially markedly elevated D-dimer in deaths with Covid-19[8]. Fei Zhou et al conducted a retrospective study involved 191 patients with Covid-19[10], and found that d-dimer greater than 1 $\mu\text{g/mL}$ on admission was associated with in-hospital death (HR:18.42, 95%CI: 2.64–128.55). Huang and colleagues showed D-dimer levels on admission were higher in patients needing critical care support than those who did not require it (median: 0.5 $\mu\text{g/ml}$ [1]. However, these previous studies did not provide well evaluated cutoff for D-dimer. Therefore, a recent guidance on recognition and management of coagulopathy in Covid-19 from International Society of Thrombosis and Haemostasis (ISTH) “arbitrarily defined markedly raised D-dimers on admission as three-four folds increase”[6]. In current study, a clear cutoff value (2.0 $\mu\text{g/ml}$, fourfold increase) for D-dimer was well established by ROC curve. Notably, of 12 non-survivors with D-dimers $\geq 2.0 \mu\text{g/ml}$, 7 of whom had no severity symptoms on admission. Thus, for patients who have markedly raised D-dimers (cut-off: 2.0 $\mu\text{g/ml}$, four-fold increase), admission to hospital and closely monitoring should be considered even in the absence of other severity symptoms.

Elevation of D-dimer indicated a hypercoagulable state in patient with Covid-19, which might be attributed to several reasons as follows. First, virus infections are usually accompanied by an aggressive pro-inflammatory response and insufficient control of an anti-inflammatory response[11]. It might induce the dysfunction of endothelial cells, resulting in excess thrombin generation[12]. Second, the hypoxia found in severe Covid-19 can stimulate thrombosis through not only increasing blood viscosity, but also a hypoxia-inducible transcription factor-dependent signaling pathway[13, 14]. Third, hospitalized patients, especially severe patients with Covid-19, were more intend to have elder ages, underlying conditions, long-term bed rest and invasive treatment et al., which were all risk factors of hypercoagulation or thrombosis[15-17]. As evidence, the lung organ dissection of critical patient with Covid-19 have reported occlusion and micro-thrombosis formation in pulmonary small vessels[18]. Forth, some patients might develop

to sepsis-induced coagulopathy or even disseminated intravascular coagulation[8, 19]. At all events, elevated D-dimer was always associated with unfavorable events[20, 21]. Previously, the lack of specificity has been regarded as a disadvantage of D-dimer [7]. However, low specificity has presently been transformed into one of its advantage in the evaluation of prognosis.

This study has several limitations. First, our study might have selection bias because it was a single-center, retrospective study, even if it had sufficient power to detect the significant differences between groups in mortality. Despite our efforts to include all qualified patients, some patients still excluded in enrollment due to absence of D-dimer level on admission. Second, due to difference of patient's size and medical resources, the lengths from illness onset to admission of the included patients might not be representative, which might influence D-dimer levels on admission. In addition, the half-life of d-dimer was approximately 8 hours[22]. Therefore, dynamic measurement of D-dimer will reveal more information. Third, the fully adjusted model analysis for HR was not performed, given the low number of events. Forth, a multiple-parameter prediction model including D-dimer and other variables might provide better predictive ability for Covid-19 patients.

Conclusion

D-dimer on admission greater than 2.0 μ g/mL (fourfold increase) could effectively predict in-hospital mortality in patients with Covid-19, which indicated D-dimer could be an early and helpful marker to improve management of Covid-19 patients.

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding this article.

Funding

This work was supported by the Wuhan Municipal Health Commission (WX19Q03).

Author contributions

LZ drafted the manuscript, LZ, XY, HL, XL and ZL collected and analysed the data, LZ and QF interpreted the data, LZ and ZZ designed the study.

Acknowledgement

The authors would like to thank all people who helped or supported Wuhan to battle against to the novel coronavirus outbreak. The authors would like to thank Xuan Zheng and Youping Chen for review of the manuscript.

Table 1. Baseline characteristics of 343 patients with Covid-19

Variable	Total n=343	D-dimer <2.0 n=276	D-dimer>2.0 n=67	p value
Age-yr. (IQR)	62.0(48.0, 69.0)	59.0 (43.5, 68.0)	70.0 (62.2, 76.0)	<0.001
Age>65 -n (%)	129 (37.6)	88 (33.0)	41 (53.9)	<0.001
Female-n (%)	174 (50.7)	145 (54.3)	29 (38.2)	0.22
Underlying conditions-n (%)	120 (35.0)	79 (29.6)	41 (53.9)	<0.001
Diabetes-n (%)	47 (13.7)	31 (11.6)	16 (21.1)	0.007
Hypertension-n (%)	76 (22.2)	50 (18.7)	26 (34.2)	<0.001
Coronary heart disease-n (%)	19 (5.5)	11 (4.1)	8 (10.5)	0.02
COPD-n (%)	8 (2.3)	4 (1.5)	4 (5.3)	0.05
Cancer-n (%)	9 (2.6)	5 (1.9)	4 (5.3)	0.08
Stroke history-n (%)	8 (2.3)	2 (0.7)	6 (7.9)	<0.001
Chronic kidney disease-n (%)	4 (1.2)	4 (1.5)	0 (0.0)	1.0
Atrial fibrillation-n (%)	4 (1.2)	2 (0.7)	2 (2.6)	0.17
Chronic liver disease-n (%)	6 (1.7)	5 (1.9)	1 (1.3)	1.0
Routine tests on admission				
White blood cell-10 ⁹ /L	6.66±4.27	6.47±4.38	7.44±3.72	0.09
Lymphocyte-10 ⁹ /L (IQR)	1.36 (0.88, 1.76)	1.44 (1.03, 1.83)	0.83 (0.58, 1.24)	<0.001
Neutrophil-10 ⁹ /L (IQR)	3.68 (2.80, 5.06)	3.51 (2.71, 4.81)	4.71 (3.42, 7.32)	<0.001
Hemoglobin-10 ⁹ /L (IQR)	127 (115, 137)	127 (117, 139)	122 (110, 134)	0.003
Platelet-10 ⁹ /L	242.8±92.3	249.3±88.6	216±102.7	0.009
CRP-mg/L (IQR)	3.22 (0.34, 22.5)	1.69 (0.32, 16.6)	13.6(1.77, 62.8)	<0.001
Direct bilirubin	4.82±1.46	4.83±1.49	4.76±1.34	0.74
ALT-U/ml	28 (16, 49)	28 (16, 47)	30.5 (17, 60)	0.34
Creatinine-μmol/L (IQR)	72 (59, 85)	70 (59, 83)	76 (64, 99)	0.026
Prothrombin time-s (IQR)	11.7(11.2, 12.3)	11.6 (11.1, 12.2)	12.3 (11.6, 13.1)	<0.001

aPTT-s	29.4±4.5	29.6±4.3	28.8±5.2	0.21
Fibrinogen-g/L (IQR)	4.1(3.1, 5.1)	4.1(3.1, 5.1)	4.3(3.2, 5.6)	0.54
D-dimer-μg/ml (IQR)	0.54 (0.20, 1.41)	0.41 (0.15, 0.69)	4.76 (2.99, 11.9)	<0.001
D-dimer≤0.5 μg/ml-n (%)	164	/	/	/
Hospital stay-days	29 (21, 30)	29 (22, 30)	29 (19, 30)	0.31
Non-survivors-n (%)	13 (3.8)	1 (0.4)	12 (15.8)	<0.001

Data are mean ± SD, median (IQR), n (%). p values were calculated by *t* test, Mann-Whitney U test, χ^2 test, or Fisher's exact test, as appropriate. IQR: inter-quartile range; COPD: chronic obstructive pulmonary disease; CRP: C-reaction protein; ALT: alanine aminotransferase; aPTT: activated partial thromboplastin time.

Table 2. C-statistic of routine tests to predict mortality in patients with Covid-19

Routine laboratory tests	C-index	95% CI
D-dimer	0.883	0.842-0.916
Lymphocyte	0.872	0.832-0.906
Prothrombin time	0.858	0.814-0.895
C-reaction protein	0.844	0.799-0.882
Platelet	0.781	0.734-0.824
Neutrophil	0.773	0.725-0.817
White blood cell	0.625	0.571-0.676
Hemoglobin	0.583	0.528-0.635
Creatinine	0.567	0.510-0.623

CI: confidential interval

Figure 1. Receiver operator characteristic curve for D-dimer to predict deaths

The optimum cutoff point, identified as the point closest to upper left corner, was 2.0 µg/ml with 92.3% for sensitivity and 83.3% for specificity. Area under receiver operator characteristic curve for mortality was 0.89.

Figure 2. Kaplan-Meier survival curves for D-dimer levels on admission

Statistical significance of separation between two groups was achieved at seven days after admission. HR: Hazard ratio;

Reference

- 1 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020; **395**: 497-506. 10.1016/S0140-6736(20)30183-5.
- 2 Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Jama*. 2020; **Epub ahead of print**. 10.1001/jama.2020.1585.
- 3 Coronavirus disease (COVID-19) Pandemic. 2020.
- 4 Johns Hopkins University CSSE. The novel coronavirus (2019-nCoV) global cases 2020.
- 5 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020; **Epub ahead of print**. 10.1056/NEJMoa2002032.
- 6 Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *Journal of Thrombosis and Haemostasis*. 2020; **Epub ahead of print**. 10.1111/jth.14810.
- 7 Zhang L, Long Y, Xiao H, Yang J, Toulon P, Zhang Z. Use of D-dimer in oral anticoagulation therapy. *International journal of laboratory hematology*. 2018; **40**: 503-7. 10.1111/ijlh.12864.
- 8 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in

patients with novel coronavirus pneumonia. *Journal of thrombosis and haemostasis : JTH.* 2020; **18**: 844-7.

10.1111/jth.14768.

9 WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. 2020.

10 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020; **395**: 1054-62.

10.1016/S0140-6736(20)30566-3.

11 Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, D'Elia RV. Current and future developments in the treatment of virus-induced hypercytokinemia. *Future Med Chem.* 2017; **9**: 169-78.

10.4155/fmc-2016-0181.

12 Levi M, van der Poll T. Coagulation and sepsis. *Thrombosis research.* 2017; **149**: 38-44.

10.1016/j.thromres.2016.11.007.


13 Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. *Thrombosis research.* 2019; **181**: 77-83. 10.1016/j.thromres.2019.07.013.


14 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *Journal of thrombosis and haemostasis : JTH.* 2020; **Epub ahead of print.** 10.1111/jth.14817.

15 Harper PL, Theakston E, Ahmed J, Ockelford P. D-dimer concentration increases with age reducing the clinical value of the D-dimer assay in the elderly. *Intern Med J.* 2007; **37**: 607-13.

10.1111/j.1445-5994.2007.01388.x.

-
- 16 Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. *Journal of thrombosis and haemostasis : JTH*. 2010; **8**: 2450-7. 10.1111/j.1538-7836.2010.04044.x.
- 17 Hess K, Grant PJ. Inflammation and thrombosis in diabetes. *Thrombosis and haemostasis*. 2011; **105** Suppl 1: S43-54. 10.1160/THS10-11-0739.
- 18 China NHCotPsRo. Chinese management guideline for COVID-19 (version 6.0). The 6th edition edn, 2020.
- 19 Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M, Scientific, Standardization Committee on DIC, the S, Standardization Committee on P, Critical Care of the International Society on T, Haemostasis. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. *Journal of thrombosis and haemostasis : JTH*. 2019; **17**: 1989-94. 10.1111/jth.14578.
- 20 Zhang L, Zheng X, Long Y, Wu M, Chen Y, Yang J, Liu Z, Zhang Z. D-dimer to guide the intensity of anticoagulation in Chinese patients after mechanical heart valve replacement: a randomized controlled trial. *Journal of thrombosis and haemostasis : JTH*. 2017; **15**: 1934-41. 10.1111/jth.13782.
- 21 Tripodi A. D-dimer testing in laboratory practice. *Clinical chemistry*. 2011; **57**: 1256-62. 10.1373/clinchem.2011.166249.
- 22 Mager JJ, Schutgens RE, Haas FJ, Westermann CJ, Biesma DH. The early course of D-dimer concentration following pulmonary artery embolisation. *Thrombosis and haemostasis*. 2001; **86**: 1578-9.





Number at risk

D-dimer < 2.0 µg/ml 276	263	219	48	11
D-dimer ≥ 2.0 µg/ml 67	61	47	13	2

jth_14859_f2.tif